» Articles » PMID: 32140135

Live Birth in Woman With Premature Ovarian Insufficiency Receiving Ovarian Administration of Platelet-Rich Plasma (PRP) in Combination With Gonadotropin: A Case Report

Overview
Specialty Endocrinology
Date 2020 Mar 7
PMID 32140135
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

The conception rates among women with premature ovarian insufficiency (POI) remain extremely low. To achieve a successful pregnancy, most of these women have to receive donor oocytes through IVF treatment. Ovarian administration of platelet-rich plasma (PRP) has been recently applied to enhance the ovulatory function in women with poor ovarian response. However, no live birth has been reported for this application in patients with POI. In this study, we present a 37-year-old woman with POI who had secondary amenorrhea for 6 months. The clinical manifestations and evaluation of this women with a diminished ovarian function were an undetectable serum level of AMH (<0.02 ng/mL) and an elevated serum level of FSH (63.65 mIU/mL). A single dose of autologous PRP (extracted from 40 mL of peripheral blood) in combination with gonadotropin (150IU rFSH/75 IU rLH) was directly injected into the stroma of bilateral ovaries via vaginal sonographic guidance. Following the treatment, this patient received controlled ovarian stimulation and IVF during the successive months. Following embryo culture, three cleavage-stage embryos were transferred, leading to a successful pregnancy, which later resulted in the live birth of twins. This case report provides one example of alternative therapy that allows POI patients to use autologous oocytes in IVF treatment.

Citing Articles

Novel Advances in Cell-Free Therapy for Premature Ovarian Failure (POF): A Comprehensive Review.

Yahyavi Y, Kheradi N, Karimi A, Ebrahimi-Kalan A, Ramezani F, Yousefi S Adv Pharm Bull. 2024; 14(3):543-557.

PMID: 39494249 PMC: 11530876. DOI: 10.34172/apb.2024.059.


Platelet-rich plasma (PRP) treatment of the ovaries significantly improves fertility parameters and reproductive outcomes in diminished ovarian reserve patients: a systematic review and meta-analysis.

Elias M, Konya M, Kekk Z, Turan C, das Virgens I, Toth R J Ovarian Res. 2024; 17(1):104.

PMID: 38760869 PMC: 11100055. DOI: 10.1186/s13048-024-01423-2.


Enhancement of Ovarian Reserve and Oocyte Quality After Platelet-Rich Plasma Instillation in a Woman With Diminished Anti-Müllerian Hormone.

Shrivastava J, More A, Shrivastava V, Choudhary N, Shrivastava D Cureus. 2024; 16(2):e53474.

PMID: 38440028 PMC: 10910621. DOI: 10.7759/cureus.53474.


Clinical Application of Platelet Concentrates in Bovine Practice: A Systematic Review.

Caterino C, Della Valle G, Aragosa F, Cavalli S, Guccione J, Lamagna F Vet Sci. 2023; 10(12).

PMID: 38133237 PMC: 10747389. DOI: 10.3390/vetsci10120686.


Autologous Platelet-Rich Plasma (PRP) Efficacy on Endometrial Thickness and Infertility: A Single-Centre Experience from Romania.

Huniadi A, Zaha I, Naghi P, Stefan L, Sachelarie L, Bodog A Medicina (Kaunas). 2023; 59(9).

PMID: 37763650 PMC: 10533168. DOI: 10.3390/medicina59091532.


References
1.
Wang T, Yan L, Yan J, Lu C, Xia X, Yin T . Basic fibroblast growth factor promotes the development of human ovarian early follicles during growth in vitro. Hum Reprod. 2014; 29(3):568-76. DOI: 10.1093/humrep/det465. View

2.
Sfakianoudis K, Simopoulou M, Nitsos N, Rapani A, Pantou A, Vaxevanoglou T . A Case Series on Platelet-Rich Plasma Revolutionary Management of Poor Responder Patients. Gynecol Obstet Invest. 2018; 84(1):99-106. DOI: 10.1159/000491697. View

3.
Wu Q, Li H, Zhu Y, Jiang W, Lu J, Wei D . Dosage of exogenous gonadotropins is not associated with blastocyst aneuploidy or live-birth rates in PGS cycles in Chinese women. Hum Reprod. 2018; 33(10):1875-1882. DOI: 10.1093/humrep/dey270. View

4.
Chahla J, Cinque M, Piuzzi N, Mannava S, Geeslin A, Murray I . A Call for Standardization in Platelet-Rich Plasma Preparation Protocols and Composition Reporting: A Systematic Review of the Clinical Orthopaedic Literature. J Bone Joint Surg Am. 2017; 99(20):1769-1779. DOI: 10.2106/JBJS.16.01374. View

5.
Karlsson M, Wade J, Loumaye E, Munafo A . The population pharmacokinetics of recombinant- and urinary-human follicle stimulating hormone in women. Br J Clin Pharmacol. 1998; 45(1):13-20. PMC: 1873998. DOI: 10.1046/j.1365-2125.1998.00644.x. View